{"id":17901,"date":"2014-10-01T13:50:01","date_gmt":"2014-10-01T17:50:01","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/national-law-journal-names-weitz-and-luxenberg-elite-trial-lawyers-list-reveals-2-keys-firms-9-billion-actos-verdict-2014-10-1001-001\/"},"modified":"2014-10-01T13:50:01","modified_gmt":"2014-10-01T17:50:01","slug":"national-law-journal-names-weitz-and-luxenberg-elite-trial-lawyers-list-reveals-2-keys-firms-9-billion-actos-verdict-2014-10-1001-001","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/national-law-journal-names-weitz-and-luxenberg-elite-trial-lawyers-list-reveals-2-keys-firms-9-billion-actos-verdict-2014-10-1001-001\/","title":{"rendered":"National Law Journal Names Weitz and Luxenberg to &#8216;Elite Trial Lawyers&#8217; List, Reveals 2 Keys to Firm&#8217;s $9-Billion Actos Verdict"},"content":{"rendered":"<p>NEW YORK, N.Y., Oct. 1, 2014 (SEND2PRESS NEWSWIRE) &#8212; Two keys that earlier this year led to a $9-billion courtroom victory by Weitz &amp; Luxenberg, P.C., against the maker of the diabetes drug Actos, were revealed Monday when National Law Journal named the New York City-based personal injury firm to its debut list of &#8220;America&#8217;s Elite Trial Lawyers.&#8221;<\/p>\n<p> Key Number One &#8211; a massive investment of time devoted to pre-trial preparation in order to anticipate and thwart attempts by the defendant&#8217;s legal team to spring surprises on the Weitz &amp; Luxenberg lawyers. <\/p>\n<p> Key Number Two &#8211; at all times being truthful and honest with the jury. <\/p>\n<p> National Law Journal divulged these success keys in a Sept. 29 article introducing its inaugural list of the nation&#8217;s Top 50 plaintiffs&#8217; law firms. <\/p>\n<p> The list of &#8220;America&#8217;s Elite Trial Lawyers&#8221; was compiled by the journal in cooperation with the legal-focused news website <a href=\"http:\/\/Law.com\" rel=\"nofollow\">Law.com<\/a>. <\/p>\n<p> Merely to be considered for this list, a law firm needed to show at least one recent big verdict or settlement arising from a high-stakes case.<\/p>\n<p> In addition, list hopefuls needed a legacy of impressive victories over the span of the last five years.<\/p>\n<p> Comments obtained by National Law Journal from Weitz &amp; Luxenberg client Terrence Allen, plaintiff in the Actos case, are illustrative. <\/p>\n<p> &#8220;Day after day [the Weitz &amp; Luxenberg lawyers] were there, always prepared, always ready,&#8221; Allen was quoted by the journal as saying. <\/p>\n<p> &#8220;Not once were the lawyers on the defense able to do something that caught [my lawyers] by surprise. I often wonder how many exhausting hours of preparation [were] done to be that good.&#8221; <\/p>\n<p> Delving deeper into the law firm&#8217;s success secrets, the publication learned that Weitz &amp; Luxenberg fills its attorney ranks with former government prosecutors and other lawyers who know what it takes to bring wrongdoers to justice. <\/p>\n<p> &#8220;[Attorneys we recruit] have a lot of trial experience when they come to us,&#8221; co-founding member Perry Weitz told National Law Journal. <\/p>\n<p> The periodical noted that Weitz &amp; Luxenberg employs dozens of such heavy-hitters. <\/p>\n<p> Among those it mentioned by name were Paul Pennock, who manages Weitz &amp; Luxenberg&#8217;s Drug &amp; Medical Device Litigation group, and associate attorney Jonathan Sedgh.<\/p>\n<p> Pennock is a lead lawyer in the firm. He, Mark Lanier and Richard Arsenault served as lead lawyers in the case against Actos. <\/p>\n<p> National Law Journal also observed that Weitz &amp; Luxenberg exerts a national presence, thanks to offices in Manhattan, Los Angeles and just outside Philadelphia in Cherry Hill, New Jersey.<\/p>\n<p> National Law Journal and Law.com decided to create the &#8220;America&#8217;s Elite Trial Lawyers&#8221; roster in order to identify and lionize the 50 plaintiffs&#8217; law firms responsible for the combined total of $10 billion in recoveries won at trial during 2013 alone.<\/p>\n<p> The two organizations contend that the work of firms like Weitz &amp; Luxenberg will likely yield 2014 recoveries surpassing those of the previous year.<\/p>\n<p> <strong>About Weitz &amp; Luxenberg:<\/strong><br \/> Weitz &amp; Luxenberg, P.C., is among the nation&#8217;s leading and most readily recognized personal injury law firms. Weitz &amp; Luxenberg&#8217;s numerous litigation areas include: mesothelioma, defective medicine and devices, environmental pollutants, accidents, personal injury, and medical malpractice. Victims of accidents are invited to rely on Weitz &amp; Luxenberg&#8217;s more than 25 years of experience handling such cases. You can contact the firm&#8217;s Client Relations department at 800-476-6070 or at clientrelations@weitzlux.com.<\/p>\n<p> More information: <a href=\"http:\/\/www.weitzluxenberg.com\/\">http:\/\/www.weitzluxenberg.com\/<\/a>.<\/p>\n<p>News issued by: Weitz and Luxenberg, P.C.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.send2press.com\/wire\/images\/14-0924-weitz-luxe-500x375.jpg\" width=\"500\" height=\"375\" alt=\"Weitz and Luxenberg, P.C.\"\/><\/p>\n<p><small>Original Image: <a href=\"https:\/\/www.send2press.com\/wire\/images\/14-0924-weitz-luxe-500x375.jpg\" class=\"autohyperlink\" rel=\"nofollow\">https:\/\/www.send2press.com\/wire\/images\/14-0924-weitz-luxe-500&#215;375.jpg<\/a><\/small><\/p>\n<p> # # # <\/p>\n<p><small>Original Story ID: 2014-10-1001-001 (9663) :: national-law-journal-names-weitz-and-luxenberg-elite-trial-lawyers-list-reveals-2-keys-firms-9-billion-actos-verdict-2014-10-1001-001<\/small><\/p>\n<p><small>Original Keywords: National Law Journal, NY trial lawyers Weitz and Luxenberg, P.C. New York New York NEW YORK, N.Y.<\/small><\/p>\n<p><small>Alternate Headline: National Law Journal names New York City-based personal injury firm Weitz and Luxenberg &#8216;Elite Trial Lawyers&#8217;<\/small><\/p>\n<p><small><strong>NEWS ARCHIVE NOTE:<\/strong> this archival news content, issued by the news source via Send2Press Newswire, was originally located in the Send2Press&reg; 2004-2015 2.0 news platform and has been permanently converted\/moved (and redirected) into our 3.0 platform. Also note the story &#8220;reads&#8221; counter (bottom of page) does not include any data prior to Oct. 30, 2016. This press release was originally published\/issued: Wed, 01 Oct 2014 13:50:01 +0000<\/p>\n<p><\/small><\/p>\n<p><code><small>Original Shortcode for Story: http:\/\/i.send2press.com\/BUHg8<\/small><\/code><\/p>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, N.Y., Oct. 1, 2014 (SEND2PRESS NEWSWIRE) &#8212; Two keys that earlier this year led to a $9-billion courtroom victory by Weitz and Luxenberg, P.C., against the maker of the diabetes drug Actos, were revealed Monday when National Law Journal named the New York City-based personal injury firm to its debut list of &#8216;America&#8217;s Elite Trial Lawyers.&#8217;<\/p>\n","protected":false},"author":9780,"featured_media":17850,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[67,1,571,61,25,8,19],"tags":[],"class_list":["post-17901","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-awards-and-honors-news","category-business-news","category-pharma-news","category-health-medical-news","category-legal-and-law-news","category-new-york-news","category-us-news","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":4201,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/17901","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/9780"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=17901"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/17901\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media\/17850"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=17901"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=17901"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=17901"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}